Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of regorafenib

A technology of regorafenib and quantitative ratio, applied in the field of preparation of regorafenib, can solve the problems of unsuitable industrial production, expensive catalyst, difficult operation, etc., achieve high conversion rate, reduce production cost, and high reaction yield Effect

Active Publication Date: 2018-12-14
SHANDONG LUOXIN PHARMA GRP HENGXIN PHARMA CO LTD
View PDF15 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] The technical problem to be solved by the present invention is to provide a kind of regorafenib in order to overcome the defects of complex process, difficult operation, low yield, low purity, expensive catalyst and unsuitable for industrial production in the existing technology for preparing regorafenib. The preparation method of Gorfenib

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of regorafenib
  • Preparation method of regorafenib
  • Preparation method of regorafenib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0024] The synthesis of embodiment 1-1 intermediate I

[0025] In a 250mL three-neck flask with a magnetic stirring device, a thermometer and a reflux condenser, add 100mmol of 4-amino-3-fluorophenol, 100mmol of anhydrous potassium carbonate, and 85mmol of 4-chloro-N-methylpyridine-2- Formamide, 2.5mmol of PEG-400 and 100mL of dichloroethane were stirred electromagnetically, and heated to reflux in a water bath for 4 hours. Cool, filter, dichloroethane was evaporated under reduced pressure with a water pump, the still liquid was extracted with 240mL ether, dried, and concentrated to obtain 21.39g of a light yellow liquid, Intermediate I, with a yield of 96.3% and a purity of 99.90%.

Embodiment 1-2

[0026] The synthesis of embodiment 1-2 intermediate I

[0027] In a 250mL three-neck flask with a magnetic stirring device, a thermometer and a reflux condenser, add 90mmol of 4-amino-3-fluorophenol, 100mmol of anhydrous potassium carbonate, and 90mmol of 4-chloro-N-methylpyridine-2- Formamide, 2mmol of PEG-400 and 100mL of dichloroethane were stirred electromagnetically, and heated to reflux in a water bath for 4 hours. Cool, filter, dichloroethane was evaporated under reduced pressure with a water pump, the still liquid was extracted with 240mL ether, dried, and concentrated to obtain 21.32g of a light yellow liquid, namely Intermediate I, with a yield of 90.6% and a purity of 99.80%.

Embodiment 1-3

[0028] Synthesis of Example 1-3 Intermediate I

[0029] In a 250mL three-neck flask with a magnetic stirring device, a thermometer and a reflux condenser, add 110mmol of 4-amino-3-fluorophenol, 100mmol of anhydrous potassium carbonate, and 80mmol of 4-chloro-N-methylpyridine-2- Formamide, 3mmol of PEG-400 and 100mL of dichloroethane were stirred electromagnetically, and heated to reflux in a water bath for 4 hours. Cool, filter, dichloroethane was evaporated under reduced pressure with a water pump, and the still liquid was extracted with 240 mL of ether, dried, and concentrated to obtain 19.59 g of a light yellow liquid, namely Intermediate I, with a yield of 93.7% and a purity of 99.76%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of regorafenib. The method comprises steps as follows: 4-amino-3-fluorophenol and 4-chloro-N-methylpyridine-2-formamide are subjected to ether condensation reaction under the action of anhydrous potassium carbonate and PEG-400, and an intermediate I is generated; then the intermediate I and 3-trifluoromethyl 4-chlorobenzoic acid are subjected to one-pot reaction with diphenylphosphoryl azide under the action of alkali, a crude regorafenib product is obtained and further purified, and a pure regorafenib product is obtained. The method is high in conversion rate, safe, harmless, pollution-free, high in yield and suitable for industrial production, the reaction conditions are mild, and the product purity is high.

Description

technical field [0001] The invention relates to the field of drug synthesis, in particular to a preparation method of regorafenib. Background technique [0002] Regorafenib (regorafenib), the chemical name is 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N -Methylpyridine-2-carboxamide, developed by Bayer Healthcare in Germany, approved by the FDA in the United States, with a trade name of Stivarga. This product can inhibit a variety of kinases that promote the growth of cancer tissue, including VEGFR1-2, PDGFR-β, FGFR1 and KIT, etc., thereby inhibiting the formation of tumor angiogenesis and the proliferation of tumor cells, and is clinically suitable for the treatment of metastatic colorectal cancer . Its chemical structural formula is as follows: [0003] [0004] Several preparation methods have been reported about the synthesis of regorafenib at present, as follows: [0005] 技术方案1:专利WO2005 / 009961A、WO2008 / 89388、WO2008 / 58644、WO2011128...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D213/81
CPCC07D213/81
Inventor 刘振腾宋丽丽常志成
Owner SHANDONG LUOXIN PHARMA GRP HENGXIN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com